As of Mar 28, 2026, Remus Pharmaceuticals Ltd (Pharma - Others) has a deep value score of 53/100 (rated Average). Earnings are accelerating. 1Y return vs Nifty 500: -44%.
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Explosive revenue growth (187% YoY) combined with debt deleveraging (D/E from 1.5x to 0.53x) and margin recovery (OPM 4.68% to 7.86%) positions Remus for re-rating as operational efficiency converts top-line momentum into sustainable cash flows.
Verdict
TURNAROUND_IN_PROGRESS
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
Consensus ₹9.2cr PAT (vs ₹7.1cr YoY) confirming margin sustainability with OPM holding above 7%
Impact: +₹156.34 Cr revenue
“Management guidance on branded generics ramp-up (70% of revenue) and reduced API exposure”
₹15cr working capital facility repayment from ₹12.4cr YoY capex reduction (₹20.9cr to ₹12.4cr)
“FY25 cash flow shows ₹6.08cr financing inflow with liabilities down 1.86% YoY”
15-20% stake sale at 1.8x book value expected by August 2026 per management disclosure
“'Advanced talks' mentioned in FY25 annual report con-call transcript”
Risks that could prevent re-rating or deepen the value trap
If inventory days exceed 160 by Q2 FY26
Impact: -200 bps margin impact
Management view: Management claims inventory buildup is for export order fulfillment (USFDA clearance pending)
Monitor: QoQ inventory days trend
If pledge increases beyond 35%
Management view: Promoter states pledges are for personal investments unrelated to company operations
Monitor: Monthly pledge disclosure filings
FDA warning letter issuance
Impact: -300 bps margin impact
Management view: Management expects resolution within 60 days per con-call
Monitor: FDA inspection status updates
Forward-looking targets from management for FY26
Revenue Growth Target
120%
Implied PAT Growth
25%
OPM Guidance
8.5%
Capex Plan
₹10 Cr
Credit Growth Target
0%
NIM Guidance
0%
Key Milestones
• USFDA clearance by Q2 FY26
• Strategic investor closing by Aug 2026
• Debt-free status by Q3 FY26
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +47% | +80% | Stable |
| PAT (Net Profit) | +16% | +80% | Stable |
| OPM | 7.0% | -100 bps | Volatile |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Remus Pharmaceuticals Ltd has a deep value score of 53/100 (rated Average). This score is calculated from three components
Remus Pharmaceuticals Ltd's quarterly profit (PAT) growth trajectory
Remus Pharmaceuticals Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
Remus Pharmaceuticals Ltd's earnings momentum is Steady — consistent growth.
Remus Pharmaceuticals Ltd's valuation metrics
Remus Pharmaceuticals Ltd's revenue and margin trends
Remus Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Remus Pharmaceuticals Ltd key facts
Remus Pharmaceuticals Ltd shows limited deep value signals currently — score is 53/100 (Average). Monitor for improvement.
Other deep value stocks in Pharma - Others
Pharma - Others deep value sector overview
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
Remus Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
Remus Pharmaceuticals Ltd has 3 key risks worth monitoring
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
